Empfehlung
17,5
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
70.1
2 Insider, 387K $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Score-Verlauf (90 Tage)
Stammdaten
Unternehmen
| Name | Immunome Inc. |
|---|---|
| Ticker | IMNM |
| CIK | 0001472012 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Immunome Inc. |
Status
| Zuletzt geprüft | 2026-03-20 22:23:54.213454 |
|---|
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 6,941,000 | -212,394,000 | -2.43 | 683,188,000 | 634,343,000 |
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-23 | WAGENHEIM PHILIP | Director | Open Market Sale | -28,200 | 20.65 | -582,330.00 | -80,5% | |
| 2026-03-20 | WAGENHEIM PHILIP | Director | Open Market Sale | -36,800 | 20.47 | -753,296.00 | -104,1% | |
| 2026-03-11 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 1,000 | 21.55 | 21,550.00 | +3,0% | |
| 2026-03-11 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 1,000 | 21.55 | 21,550.00 | +3,0% | |
| 2026-03-10 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 1,000 | 22.12 | 22,120.00 | +3,1% | |
| 2026-03-10 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 1,000 | 22.12 | 22,120.00 | +3,1% | |
| 2025-12-30 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 4,729 | 21.15 | 100,018.35 | +13,8% | |
| 2025-12-30 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 4,729 | 21.15 | 100,018.35 | +13,8% | |
| 2025-12-30 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 4,729 | 21.15 | 100,018.35 | +13,8% | |
| 2025-12-22 | Barchas Isaac | Director | Open Market Sale | -11,251 | 22.34 | -251,347.34 | -34,7% | |
| 2025-12-22 | Barchas Isaac | Director | Open Market Sale | -371,949 | 21.72 | -8,078,732.28 | -1116,2% | |
| 2025-12-19 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 7,278 | 20.48 | 149,053.44 | +20,6% | |
| 2025-12-19 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 7,278 | 20.48 | 149,053.44 | +20,6% | |
| 2025-12-19 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 7,278 | 20.48 | 149,053.44 | +20,6% | |
| 2025-12-19 | Tsai Philip | Officer, Chief Technical Officer | Open Market Purchase | 10,000 | 20.49 | 204,900.00 | +28,3% | |
| 2025-12-18 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 46,511 | 21.50 | 999,986.50 | +138,2% | |
| 2025-12-18 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 46,511 | 21.50 | 999,986.50 | +138,2% | |
| 2025-12-18 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 46,511 | 21.50 | 999,986.50 | +138,2% | |
| 2025-06-03 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 5,000 | 9.38 | 46,900.00 | +6,5% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.